[无可用内容]。

[Not Available].

作者信息

Kurtz Jean-Emmanuel, D'Hondt Véronique, Lécuru Fabrice, Lhommé Catherine

机构信息

Service d'oncologie et d'hématologie, hôpitaux universitaires de Strasbourg, 1, avenue Molière, 67098 Strasbourg, France.

Département d'oncologie médicale, Institut régional du cancer de Montpellier (ICM), Val-d'Aurelle, 208, rue des Apothicaires, 34298 Monptellier, Cedex 5, France.

出版信息

Bull Cancer. 2017 May;104 Suppl 1:S39-S42. doi: 10.1016/S0007-4551(17)30161-3.

DOI:10.1016/S0007-4551(17)30161-3

PMID:28625314

Abstract

The prognosis of metastatic or recurrent cervical cancer remains dismal. The poor chemosensitivity of this tumor- is an issue, especially in case of recurrence in irradiated fields. Still, chemotherapy has shown some efficacy, and mostly consists in platinum-based doublets. The addition of bevacizumab to chemotherapy has been recently validated. However, most of these patients present with complex clinical situations and the treatment strategy has to be discussed in multidisciplinary tumor boards.

摘要

转移性或复发性宫颈癌的预后仍然不容乐观。这种肿瘤化疗敏感性差是一个问题，尤其是在放疗区域复发的情况下。尽管如此，化疗已显示出一定疗效，且大多采用铂类双联疗法。最近，化疗联合贝伐单抗已得到验证。然而，这些患者大多存在复杂的临床情况，治疗策略必须在多学科肿瘤专家委员会中进行讨论。